Industry Wire 263

April 11, 2025 Viktor Zarev 0 min read
  1. FDA shifts away from animal testing for drug development. 
  2. Prospect’s beleaguered Penn. hospitals get last-minute lifeline. 
  3. Medicare Advantage contracts squeeze rural hospitals.
  4. ‘Chaos and questions’ at U.S. health agencies. 
  5. NIH reverses conference attendance ban for scientists. 
  6. Healthcare welcomes pause to tariff turmoil. 
  7. Novartis to spend $23B on U.S. drug plants.
  8. Medicare paid Medicare Advantage $38B for non-Medicare services.
  9. Employers are willing to pay for anti-obesity meds.
  10. One-third of maternal deaths happen long after delivery.
Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Atrial Fibrillation November 10, 2025

ARREST-AF and the Importance of Lifestyle Post-Ablation November 10, 2025

Catheter ablation for atrial fibrillation might be missing half its potential, after results from the ARREST-AF trial demonstrated that structured lifestyle and risk factor management significantly increases a patient’s 12-month freedom from arrhythmia while cutting recurrence risk nearly in half. That could be changing now, thanks to the ARREST-AF trial which randomized 122 patients with […]

Heart Failure November 6, 2025

PREVENT-TAHA8 Supports Stem Cells for Post-MI HF November 6, 2025

Stem cell therapy for post-MI heart failure might deserve a second look, after the PREVENT-TAHA8 trial demonstrated that mesenchymal stem cell infusion within days of STEMI significantly reduced 3-year HF incidence. Based in Iran, the PREVENT-TAHA8 trial, randomized 396 patients following LAD STEMI with LVEF <40%, to receive either an intracoronary mesenchymal stem cell infusion […]

Structural Heart November 3, 2025

Abbott’s Tendyne TMVR System Works Even in the Sickest MR Patients November 3, 2025

New research presented at TCT 2025 suggests that Abbott’s FDA-approved Tendyne TMVR system leads to significantly better health outcomes in patients with severe mitral annular calcification who were previously considered untreatable. The SUMMIT-MAC trial enrolled 103 patients with severe MAC and found that the challenging patient population showed strong outcomes despite extreme pathology… However, patients […]